VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint disorders, including osteoarthritis. Although the company has built its business around such “autologous” treatments, its executives have long believed that the real market opportunity lies in “allogeneic,” or off-the-shelf, stem cells.
